Dr Russell Hughes
Senior Postdoctoral Research Associate
Department of Oncology & Metabolism
Academic Unit of Inflammation & Tumour Targeting
University of Sheffield Medical School
Beech Hill Road
Telephone: +44 (0) 114 271 2473
Fax: +44 (0) 114 271 3314
Since completing my PhD in the department of Infection & Immunity at the University of Sheffield in 2009, I have held two postdoctoral positions focussing on anti-cancer therapy, based in the Academic Unit of Inflammation & Tumour Targeting. The first appointment in 2009 was an industrial collaborative project with Astra Zeneca, to develop new screening systems for the identification of novel anti-cancer therapies. In 2011, I was appointed to a CRUK-funded research project to investigate the role of the immune system in the relapse of surgically inoperable cancers. Most recently, we have been awarded an YCR project grant to develop new strategies to suppress cancer relapse after chemotherapy by targeting tumour infiltrating immune cells.
My research interests focus on investigating how the interactions between the various immune cells present within cancers, with an emphasis on the tumour macrophage, influence both a patient's initial response to anti-cancer therapy and how these interactions support the relapse of surgically inoperable cancers following treatment. My research involves investigating how tumour macrophages help cancers to avoid destruction by the immune system and how tumour macrophages support both the initial growth and relapse of cancers after therapy by regulating their vascular supply. These studies will aid in the development of new treatments designed to block cancer supporting immune cell and blood vessel interactions. This research has received recent media attention:-http://www.dailymail.co.uk/health/article-3195745/How-body-defences-block-chemo.html and http://www.bbc.co.uk/news/health-33957105
Tumour microenvironment: Immunology and Angiogenesis
EU Marie Curie ITN Project Grant: Image Guided Surgery and Personalised Postoperative Immunotherapy to Improve Cancer Outcome (2015-2019) Co-I.
Yorkshire Cancer Research: Prevention of Tumour Regrowth and Spread after Chemotherapy by Inhibiting Tumour Repair by Macrophages (2015-2018). Co-I.
Innovation, Impact and Knowledge Exchange Award: The Role of Perivascular Macrophages in Modulating the Effect of CXCR4 Antagonists on Tumour Regrowth after Chemotherapy (2014-2015) Co-PI.
Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard J and Lewis CE. Perivascular M2 macrophages Stimulate Tumor Relapse After Chemotherapy. Cancer Res. (Published online, Aug 12th 2015).
Muthana M, Kennerley AJ, Richardson J, Paul M, Murdoch C, Lunj S, Hughes R, Farrow N, Dobson J, Pankhurst Q, Lythgoe M, Wild J and Lewis CE. (2015). Directing cell therapy to anatomic sites in vivo with magnetic resonance targeting. Nature Commun. (Published online, Aug 18th 2015).
Haider MT, Hunter KD, Robinson SP, Graham TJ, Corey E, Dear TN, Hughes R, Brown NJ, Holen I. Rapid modification of the bone microenvironment following short-term treatment with Cabozantanib in vivo. Bone (in press).
Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Ottewell PD, Holen I. (2013). Macrophages as Potential Targets for Zoledronic Acid Outside the Skeleton – Evidence from in vitro and in vivo Models. Cellular Oncology 36:505-14.
Muthana M, Rodrigues S, Chen YY, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE. (2013). Macrophage Delivery of an Oncolytic Virus Abolishes Tumour Regrowth and Metastasis After Chemotherapy or Irradiation. Cancer Res. 73:490-495
Fang HY, Hughes R, Murdoch C, Coffelt S, Bsiwas SK, Harris AL, Johnson RS, Imityaz HZ, Simon MC, Fredlund E, Greten R, Rius K, Lewis CE. Hypoxia Inducible Factors 1 and 2 are Important Transcriptional Effectors in Primary Macrophages Experiencing Hypoxia. Blood 114:844-859.